Johnson & Johnson (NYSE:JNJ) One Johnson & Johnson Plaza New Brunswick, NJ 08933 Phone: (732) 524-0400 Fax: (732) 214-0332 http://www.jnj.com
Johnson & Johnson was incorporated in the State of New Jersey in 1887. The Company is engaged in the research and development, manufacture and sale of a range of products in the health care field. It is a holding company, which has more than 250 operating companies conducting business in virtually all countries of the world. Johnson. Johnson & Johnson's operating companies are organized into three business segments: Consumer, Pharmaceutical and Medical Devices and Diagnostics. The Consumer segment includes a range of products used in the baby care, skin care, oral care, wound care and women's health care fields, as well as nutritional and over-the-counter pharmaceutical products. The Baby Care franchise includes the JOHNSON'S(r) Baby line of products. Major brands in the Skin Care franchise include the AVEENO(r); CLEAN & CLEAR(r); JOHNSON'S(r) Adult; NEUTROGENA(r); RoC(r); LUBRIDERM(r); Beijing Dabao Cosmetics Co., Ltd.; and Vendome product lines. The Oral Care franchise includes the LISTERINE(r) and REACH(r) oral care lines of products. Major brands in the Women"s Health franchise are the CAREFREE(r) Pantiliners and STAYFREE(r) sanitary protection products. The nutritional and over-the-counter lines include SPLENDA(r), No Calorie Sweetener; the family of TYLENOL(r) acetaminophen products; SUDAFED(r) cold, flu and allergy products; ZYRTEC(r) allergy products; MOTRIN(r) IB ibuprofen products; and PEPCID(r) AC Acid Controller from Johnson & Johnson Merck Consumer Pharmaceuticals Co. The Pharmaceutical segment includes products in the following therapeutic areas: anti-infective, antipsychotic, cardiovascular, contraceptive, dermatology, gastrointestinal, hematology, immunology, neurology, oncology, pain management, urology and virology. Key products in the Pharmaceutical segment include: REMICADE(r) a biologic approved for the treatment of Crohn's disease, ankylosing spondylitis, psoriasis, psoriatic arthritis, ulcerative colitis, and use in the treatment of rheumatoid arthritis; TOPAMAX(r) approved for adjunctive and monotherapy use in epilepsy, as well as for the prophylactic treatment of migraines; PROCRIT(r) biotechnology-derived product that stimulates red blood cell production; RISPERDAL(r) oral a medication that treats the symptoms of schizophrenia, bipolar mania and irritability associated with autistic behavior in indicated patients. RISPERDAL(r) CONSTA(r), a long-acting injectable, and INVEGATM Extended-Release tablets, for the treatment of schizophrenia; LEVAQUIN(r) and FLOXIN(r), both in the anti-infective field; CONCERTA(r), a product for the treatment of attention deficit hyperactivity disorder; ACIPHEX(r)/PARIET(r), a proton pump inhibitor co-marketed with Eisai Inc.; and DURAGESIC(r)/Fentanyl Transdermal a treatment for chronic pain that offers a novel delivery system. The Medical Devices and Diagnostics segment includes a range of products distributed to wholesalers, hospitals and retailers, used mainly in the professional fields by physicians, nurses, therapists, hospitals, diagnostic laboratories and clinics. In all of their product lines, Johnson & Johnson's operating companies compete with companies large and small, located throughout the world. Most of Johnson & Johnson's businesses are subject to varying degrees of governmental regulation in the countries in which operations are conducted, and the general trend is toward increasingly stringent regulation.
BUYandHOLD does not offer or provide any investment advice
or opinion regarding the nature, potential, value, suitability
or profitability of any particular security, portfolio of
securities, transaction or investment strategy. Any investment
decisions you make will be based solely on your evaluation
of your financial circumstances, investment objectives, risk
tolerance, and liquidity needs. The security and information
listed above and is being provided for informational purposes
only and should not be regarded as an offer to sell or as
a solicitation of an offer to buy and past performance is
no guarantee of future results.
The BUYandHOLD
website contains links to third-party websites on the Internet.
BUYandHOLD provides these links to these websites only as
a convenience to users of the website. Links on the BUYandHOLD
website are not endorsements by BUYandHOLD or Freedom Investments,
implied or express, of the linked sites or any products, services
or links in such sites; and no information in such sites has
been endorsed or approved by BUYandHOLD. Linked sites are
not under the control of BUYandHOLD or Freedom Investments,
and we are not responsible for the contents of any linked
site or any link contained in a linked site. No information
contained in the BUYandHOLD website or accessed through any
linked site, or any link contained in a linked site, constitutes
a recommendation by BUYandHOLD or Freedom Investments to buy,
sell or hold any security, financial product or instrument.
Information accessed through linked sites is not, nor should
be construed as, an offer or a solicitation of an offer, to
buy or sell securities by BUYandHOLD or Freedom Investments.
BUYandHOLD does not offer or provide any investment advice
or opinion regarding the nature, potential, value, suitability
or profitability of any particular security, portfolio of
securities, transaction or investment strategy, and any investment
decisions you make will be based solely on your evaluation
of your financial circumstances, investment objectives, risk
tolerance, and liquidity needs.
